Dr. Tanya Siddiqi

Hematology
1500 E Duarte Rd, 
Duarte, CA 
Offers Telehealth
1500 E Duarte Rd, 
Duarte, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Tanya Siddiqi is a Hematologist in Duarte, California. Dr. Siddiqi is rated as an Experienced provider by MediFind in the treatment of Infantile Neutropenia. Her top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 111 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

CITY OF HOPE MEDICAL FOUNDATION
1500 E Duarte Rd, Duarte, CA 91010
Other Locations
CITY OF HOPE MEDICAL FOUNDATION
1500 Duarte Rd, Duarte, CA 91010
CITY OF HOPE MEDICAL FOUNDATION
1601 Avocado Ave, Newport Beach, CA 92660
CITY OF HOPE MEDICAL FOUNDATION
209 Fair Oaks Ave, South Pasadena, CA 91030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: November 07, 2025
Intervention Type: Drug, Biological
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients With CD19+ B-Cell Lymphoproliferative Neoplasms
Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients With CD19+ B-Cell Lymphoproliferative Neoplasms
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Drug, Biological
Study Drugs: CD19CAR-CD28-CD3zeta-EGFRt-Expressive Tn/Mem-Enriched T Lymphocytes, Bendamustine, Cyclophosphamide, Etoposide, Fludarabine
Study Phase: Phase 1
A Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
A Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Enrollment Status: Completed
Publish Date: February 12, 2025
Intervention Type: Drug
Study Drugs: Cirmtuzumab, Ibrutinib
Study Phase: Phase 1/Phase 2
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drugs: BGB-3111 (Zanubrutinib), Ibrutinib
Study Phase: Phase 3
A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Completed
Publish Date: June 27, 2024
Intervention Type: Biological
Study Drug: JCAR017 (Lisocabtagene Maraleucel) 
Study Phase: Phase 1
A Phase 1 / 2 Study to Evaluate the Safety and Tolerability of Adoptively Transferred Autologous T Cells in Patients With Relapsed Refractory Multiple Myeloma
A Phase 1 / 2 Study to Evaluate the Safety and Tolerability of Adoptively Transferred Autologous T Cells in Patients With Relapsed Refractory Multiple Myeloma
Enrollment Status: Suspended
Publish Date: January 16, 2024
Intervention Type: Biological
Study Drug: NEXI-002 T Cells
Study Phase: Phase 1/Phase 2
Phase II Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia
Phase II Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia
Enrollment Status: Completed
Publish Date: May 11, 2022
Intervention Type: Drug
Study Drug: ABT199
Study Phase: Phase 2
View 8 Less Clinical Trials

111 Total Publications

The role of MRD monitoring and options for CLL management in relapsed/refractory disease.
The role of MRD monitoring and options for CLL management in relapsed/refractory disease.
Journal: Hematology. American Society of Hematology. Education Program
Published: December 05, 2025
Similar Doctors
Advanced in Infantile Neutropenia
Dr. Etan Orgel
Pediatrics | Hematology | Oncology
Advanced in Infantile Neutropenia
Dr. Etan Orgel
Pediatrics | Hematology | Oncology
4650 W Sunset Blvd # 54, 
Los Angeles, CA 
 (18.3 miles away)
323-361-2121
Languages Spoken:
English
See accepted insurances

Etan Orgel is a Pediatrics specialist and a Hematologist in Los Angeles, California. Dr. Orgel is rated as an Advanced provider by MediFind in the treatment of Infantile Neutropenia. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Infantile Neutropenia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Experienced in Infantile Neutropenia
Dr. Robert R. Jenq
Hematology | Hematology Oncology | Oncology
Experienced in Infantile Neutropenia
Dr. Robert R. Jenq
Hematology | Hematology Oncology | Oncology

City Of Hope Medical Foundation

1500 Duarte Rd, 
Duarte, CA 
 (0.1 miles away)
626-256-4673
Languages Spoken:
English
See accepted insurances

Robert Jenq is a Hematologist and a Hematologist Oncology provider in Duarte, California. Dr. Jenq is rated as a Distinguished provider by MediFind in the treatment of Infantile Neutropenia. His top areas of expertise are Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Agranulocytosis, Bone Marrow Transplant, and Bone Marrow Aspiration.

Experienced in Infantile Neutropenia
Dr. Robert M. Cooper
Pediatric Hematology Oncology | Oncology | Pediatrics
Experienced in Infantile Neutropenia
Dr. Robert M. Cooper
Pediatric Hematology Oncology | Oncology | Pediatrics

Kaiser Permanente Los Angeles Medical Center - Pediatrics Department

4950 W Sunset Blvd, 
Los Angeles, CA 
 (18.7 miles away)
833-574-2273
Languages Spoken:
English
See accepted insurances

Robert Cooper is an Oncologist and a Pediatrics provider in Los Angeles, California. Dr. Cooper is rated as an Advanced provider by MediFind in the treatment of Infantile Neutropenia. His top areas of expertise are Leukemia, Hepatoblastoma, Reticulohistiocytoma, Histiocytosis, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Siddiqi's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 10 Distinguished Conditions
View All 19 Advanced Conditions
View All 34 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile